tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Genmab receives FDA Breakthrough Therapy Designation for rinatabart sesutecan
The FlyGenmab receives FDA Breakthrough Therapy Designation for rinatabart sesutecan
2d ago
GMAB
Genmab’s Strategic Growth and Clinical Advancements: A Compelling Investment Opportunity
PremiumRatings
Genmab’s Strategic Growth and Clinical Advancements: A Compelling Investment Opportunity
13d ago
GMAB
Genmab’s Strong Financial Performance and Promising Pipeline Drive Buy Rating
PremiumRatings
Genmab’s Strong Financial Performance and Promising Pipeline Drive Buy Rating
13d ago
GMAB
Genmab price target raised to $36 from $35 at H.C. Wainwright
PremiumThe Fly
Genmab price target raised to $36 from $35 at H.C. Wainwright
13d ago
GMAB
Genmab’s Strong Financial Performance and Promising Pipeline Drive Buy Rating
PremiumRatings
Genmab’s Strong Financial Performance and Promising Pipeline Drive Buy Rating
21d ago
GMAB
Genmab’s Strong Performance and Future Uncertainties: A Balanced Hold Rating by Yaron Werber
PremiumRatingsGenmab’s Strong Performance and Future Uncertainties: A Balanced Hold Rating by Yaron Werber
21d ago
GMAB
Genmab reports Q2 operating income $360M, consensus $322M
Premium
The Fly
Genmab reports Q2 operating income $360M, consensus $322M
21d ago
GMAB
Genmab raises 2025 sales outlook to $3.5B-$3.7B from $3.34B-$3.66B
Premium
The Fly
Genmab raises 2025 sales outlook to $3.5B-$3.7B from $3.34B-$3.66B
21d ago
GMAB
Genmab says Phase 3 EPCORE FL-1 trial met dual primary endpoints
PremiumThe Fly
Genmab says Phase 3 EPCORE FL-1 trial met dual primary endpoints
21d ago
GMAB
Genmab reports Q2 worldwide net sales of Darzalex $3.54B
PremiumThe Fly
Genmab reports Q2 worldwide net sales of Darzalex $3.54B
1M ago
JNJ
GMAB
Genmab price target raised to $46 from $45 at Truist
PremiumThe Fly
Genmab price target raised to $46 from $45 at Truist
2M ago
GMAB
Genmab CLO Birgitte Stephensen to retire, Greg Mueller to succeed
PremiumThe Fly
Genmab CLO Birgitte Stephensen to retire, Greg Mueller to succeed
2M ago
AZN
GMAB
Genmab announces new results fom Phase 1b/2 EPCORE NHL-2 trial
PremiumThe FlyGenmab announces new results fom Phase 1b/2 EPCORE NHL-2 trial
2M ago
GMAB
Genmab price target lowered to DKK 1,500 from DKK 1,700 at JPMorgan
Premium
The Fly
Genmab price target lowered to DKK 1,500 from DKK 1,700 at JPMorgan
3M ago
GMAB
Genmab reports ‘encouraging anti-tumor activity’ for Rina-S in Phase 1/2 trial
Premium
The Fly
Genmab reports ‘encouraging anti-tumor activity’ for Rina-S in Phase 1/2 trial
3M ago
GMAB
Genmab price target lowered to DKK 2,000 from DKK 2,300 at RBC Capital
PremiumThe Fly
Genmab price target lowered to DKK 2,000 from DKK 2,300 at RBC Capital
3M ago
GMAB
Genmab’s Promising Rina-S Developments Drive Buy Rating Amid Strong Initial Study Results
PremiumRatings
Genmab’s Promising Rina-S Developments Drive Buy Rating Amid Strong Initial Study Results
3M ago
GMAB
Genmab’s Rina-S: Promising Efficacy and Strategic Growth Potential in Endometrial Cancer Treatment
PremiumRatings
Genmab’s Rina-S: Promising Efficacy and Strategic Growth Potential in Endometrial Cancer Treatment
3M ago
GMAB
Bolt Biotherapeutics initiated with a Buy at Lake Street
PremiumThe Fly
Bolt Biotherapeutics initiated with a Buy at Lake Street
3M ago
BOLT
GMAB
Genmab’s Strategic Forecast and Pipeline Potential Drive Buy Rating
PremiumRatingsGenmab’s Strategic Forecast and Pipeline Potential Drive Buy Rating
3M ago
GMAB
Genmab price target lowered to $35 from $37 at H.C. Wainwright
Premium
The Fly
Genmab price target lowered to $35 from $37 at H.C. Wainwright
4M ago
GMAB
Genmab’s Strong Financial Performance and Promising Pipeline Justify Buy Rating
Premium
Ratings
Genmab’s Strong Financial Performance and Promising Pipeline Justify Buy Rating
4M ago
GMAB

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >